Characterizing the myocardium of Systemic Sclerosis patients with pulmonary hypertension using CMR parametric mapping
- Conditions
- SclerodermaSystemic sclerosis1001928010003816
- Registration Number
- NL-OMON48562
- Lead Sponsor
- Radboud Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 25
- Age >=18
- Diagnosis of SSc according to the 2013 ACR-EULAR classification criteria
- Diagnosed with pulmonary hypertension WHO group 1 (PAH) and (in combination with)/or WHO group 2 (PH due to LHD) according to ESC[6]/ERS guidelines.
- Written informed consent
- Severe lung diseases (severe interstitial lung disease with a forced vital capacity <40%, COPD GOLD stadium III-IV), history of pulmonary embolisms.
- History of myocardial infarction, ischemic heart failure, moderate to severe valve stenosis or regurgitations (with or without heart failure).
- Patients with WHO group 3 PH (due to lung disease), defined as a pulmonary capillary wedge <15mmHg in combination with a forced vital capacity <60% (of 65%?) and/or moderate to severe interstitial lung disease on a high resolution computed tomography.
- Known contra-indications for CMR (e.g.: severe claustrophobia, metal implants, severe renal failure, severe astma, high degree AV-block)
- Known GFR < 30 ml/min
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method